Adaptin Bio completes alternative public offering and closes $7.7 million private placement
Adaptin Bio, Inc, a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, announced the successful completion of a reverse merger of a wholly owned subsidiary of Unite Acquisition 1 …